Among the diverse CSC populations in HCC, subpopulations marked by CD133+, CD44+, and CD90+ are particularly noteworthy for their resistance to sorafenib treatment, a common therapeutic agent used in managing HCC [68,83,84,85,86]. This evidence concerns the gene PROM1 and hepatocellular carcinoma.